NLNataliya Yu Litvinova

Nataliya Yu Litvinova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nataliya Yu Litvinova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Тransplantation of autologous stem cells, obtained from adipose tissue, in complex treatment of chronic ischemia of the lower extremities

    by V. G. Mishalov, N. Yu. Litvinova, O. I. Kefeli-Yanovska, V. A. Chernyak, D. E. Dubenko, E. A. Dzhalilova, O. I. Azarov, R. F. Kaminsky

    Objective. To investigate the efficacy of application of autologous mesenchymal stem cells (AMSC) in treatment of patients, suffering critical ischemia of the lower extremities (CILE). Маterials and methods. In 2012 - 2015 yrs there was conducted the treatment of 41 patients, suffering CILE: 22 (53.7%) - men, and 19 (46.3%) - women. In the Group I (the main) 21 (51.2%) patients have had obtained a standard course of treatment, using AMSC. In the Group II (the control one) 20 (49.8%) patients have obtained a standard course of conservative treatment, using prostaglandins of group Е1 (PGЕ1). The results were investigated, measuring ankle-brachial pressure index, and the indices of a laser duplex flowmetry and a walking distance. Results. During a one-year follow-up a trustworthy enhancement of microcirculation index was registered in the patients, who were treated, using AMSC, comparing with the patients, who obtained a course of therapy of PGЕ1 (р=0.037). Positive dynamics of the microcirculation index while a PGЕ1application was observed during (1.8 ± 0.3) mo, аnd while application of AMSC the microcirculation index have been enhanced trustworthily in (2.7 ± 0.4) mo and persisted during one-year of follow-up. Conclusion. Development of therapeutic effect in groups of patients, who were treated with AMSC and PGЕ1, did not occur simultaneously, thus , a complex treatment with simultaneous application of both methods and conduction of a dosed physical training may be considered a rational option.

  • Open Access

    ЕКСПЕРИМЕНТАЛЬНА МОДЕЛЬ ЛІКУВАННЯ ХРОНІЧНОЇ КРИТИЧНОЇ ІШЕМІЇ ТКАНИН НИЖНЬОЇ КІНЦІВКИ З ВИКОРИСТАННЯМ КУЛЬТУРИ СТОВБУРОВИХ КЛІТИН, ОДЕРЖАНИХ З ЖИРОВОЇ ТКАНИНИ

    by N. Yu. Litvinova, V. G. Міshalov, V. А. Chernyak, D. E. Dubenko, V. V. Likhodiyevskyi, А. V. Коrsak, D. О. Zubov, R. G. Vasilyev

    Вступ. Захворювання периферійних артерій (ЗПА) є важливою медико-соціальною проблемою, що потребує розробки нових видів терапії, зокрема, використання аутологічних стовбурових клітин. Мета. Вивчити морфофункціональний стан нижніх кінцівок кролів, у яких моделювали хронічну критичну ішемію тканин нижніх кінцівок (ХКІНК) та застосовували культуру аутологічних стовбурових клітин, одержаних з їх жирової тканини (ADSCs). Матеріали і методи. У дослідження включені 18 кролів-самиць, розподілених на 3 групи: псевдооперованих (І), оперованих, яким вводили ізотонічний розчин NaCl (ІІ), оперованих, яким вводили ADSCs (ІІІ). Морфофункціональний стан тазових кінцвок оцінювали за даними дуплексної флоуметрії, функціональних тестів та морфологічного дослідження. Результати. У тварин ІІІ групи спостерігали часткове відновлення функції тазової кінцівки та покращення стану м’язової тканини, чого не було у тварин ІІ групи. В ІІІ групі відзначене припинення прогресування некротичних процесів та часткова епітелізація трофічних виразок. Висновки. Використання ADSCs при моделюванні ХКІНК у кролів сприяло відновленню функції тазової кінцівки, що проявлялося якісними й кількісними змінами морфофункціональних показників через 5 тиж після введення стовбурових клітин. Ключові слова: хронічна критична ішемія тканин нижніх кінцівок; захворювання периферійних артерій; ADSCs; експеримент.

  • CELL THERAPY IN THE TREATMENT OF CRITICAL LOWER LIMB ISCHEMIA

    by Volodymyr G. Mishalov, Nataliya Litvinova

    • 29 January 2003
      • p. 49-50

    [Prophylaxis of infectious complications in reconstructive surgery of multifocal atherosclerosis in patients with critical ischemia of organs and tissues].

    by V H Mishalov, V A Cherniak, N Iu Litvinova, V M Seliuk, O I Osadchiĭ, H O Kostromin

    • 1 September 2001
      • No. 9,p. 12-4

    [Application of clexane in reconstructive surgery of the aorta arch vessels for the arterial thrombosis prophylaxis].

    by V G Mishalov, N Iu Litvinova, V M Seliuk, V A Cherniak

    Results of treatment of 114 patients for ten-year period, operated on for diseases of extracranial vessels, were adduced. Up to 1998 after performance of reconstructive operation as anticoagulant heparin was used in 80 patients and in last time--low-molecular heparin clexane in 34. After operation all patients survived. An ischemic insult occurred in 2-3 days after the operation in 2(2.5%) patients, while application of heparin, in 5--positive changes of the disease course were absent, in 19(23.75%)--postoperative hemorrhagic complications occurred. When clexane was administered in 2(5.9%) patients the cerebral hemodynamics improvement was not noted, complications in the early and late postoperative periods were absent. In term of observation up to 5 years good results was noted in 21(62.3%) patient, fair--in 9 (27.2%). In late postoperative period the brain hemodynamics improvement was not noted in 2 (5.9%) patients. Application of clexane for the arterial thrombosis prophylaxis is clinically substantiated and permits to reduce significantly the risk of the complications occurrence, which are observed with usage of heparin.

    • 1 August 2001
      • No. 8,p. 66-7

    [Aprostan application in the treatment of the diabetic foot, atherosclerotic arterial lesions in the stage of critical ischemia].

    by V H Mishalov, V M Seliuk, V A Cherviak, N Iu Litvinova

    • 1 January 2001
      • No. 5,p. 29-32

    [Clinical efficacy of alprostan in treatment of obliterating multifocal atherosclerotic affection of arteries in patients with critical ischemia of lower extremities].

    by V G Mishalov, V A Cherniak, V M Seliuk, N Iu Litvinova

    Experience of application of alprostan (PGE1, alprostadil) in 19 patients with atherosclerotic affection of vessels, chronic and acute ischemia of lower extremities in III-IV stage in combination with affection of other vascular basins was summarized. In 10 patients, to whom operative vascular reconstruction was contraindicated and/or technically unrealizable, the conservative treatment was conducted using alprostan during 12-25 days up to the clinical effect achievement (total dose up to 1.6 mg). In 9 patients after performance of conservative treatment using alprostan the vascular bed reconstruction was done. Daily infusion of alprostan in 0.1 mg dose diluted in 250-400 ml of isotonic solution of sodium chloride during 2.5-3 h with duration of course not less than 15 days and 1.2-2.2 mg total dose of preparation constitutes an optimal scheme of treatment. Good result was noted in treatment of patients in stage II of ischemia, application of alprostan in stage IV of ischemia had permitted to reduce the extremity amputation volume or to escape it on the whole, and to restore more rapidly the cutaneous integrity in the trophic disorders regions. The alprostan usage is trustworthy in patients with multifocal atherosclerosis with the cardiac coronary vessels affection in an ischemic heart disease.

    • 1 January 1998
      • p. 97-8

    [A case of multiple adamantinomas of the long bones].

    by N Iu Litvinova, O A Petronchak, L H Matlan, R V Huleĭ